1.Factors Related to Improving Activities of Daily Living and Life-Space Mobility through Visiting Rehabilitation Services : A Multi-Institutional Study in Ibaraki Prefecture, Japan
Yumiko KAMIOKA ; Hideyuki SAITO ; Yayoi IIJIMA ; Tadahiro HOSOTA ; Tomoyuki MATSUDA ; Yuuji MIURA ; Motohide ARITA ; Takashi ISAJI ; Susumu KOSEKI
The Japanese Journal of Rehabilitation Medicine 2013;50(10):831-839
Objective : This study aimed to investigate the changes in the functioning of users of visiting rehabilitation services and related factors. Methods: Among 107 users in 22 visiting rehabilitation centers, we analyzed the data of 80 who completed the 6-month study. Their Functional Independence Measure (FIM), Life-Space Assessment (LSA), and level of caregiver burden (J-ZBI_8) were compared at the commencement of this study, and at 3 and 6 months afterwards. A multiple linear regression analysis was performed to examine the factors related to the variables, which changed over 6 months. Results : Over a period of 6 months from the commencement of the study, we found that FIM and LSA scores significantly improved from 82.4 to 87.3 (p=0.016) and from 9.9 to 12.3 (p=0.05), respectively, in the group who were still within 1 year from the time since onset/injury. A multiple regression analysis revealed that the period of time since onset/injury, independence degree of daily living for the demented elderly, and presence of goal setting for activities of daily living/domestic work significantly influenced changes in total FIM scores (p=0.001, R2=0.32). Furthermore, the change in LSA scores was significantly influenced by gender, presence of cerebrovascular diseases, period of time since onset/injury, number of occupations involved in visiting rehabilitation services, and J-ZBI_8 scores (p=0.0001, R2=0.36). Conclusion : Effective visiting rehabilitation requires having appropriate goals set for daily living activities and the establishment of interprofessional collaboration within visiting rehabilitation centers.
2.Results of gastric mass survey in Tsuchiura Kyodo Hospital.
Katsuhiro Sanada ; Mamoru Takeshi ; Koji Koike ; Kazuo Hirose ; Koichi Matsuda ; Yoshio Ishida ; Yoji Nakazawa ; Masahiro Tsubaki ; Tomoyuki Suzuki ; Kazushi Seki ; Susumu Hiranuma ; Koichi Shibata ; Kohei Okamoto ; Shin Tonouchi
Journal of the Japanese Association of Rural Medicine 1985;33(5):907-912
We began gastric mass survey at our hospital in May, 1980. During 3 years and 8 months since then, (May, 1980-December, 1983) we performed screening examinations to 16, 341 people by indirect radiography, and checked 2, 824 cases (17.3%) for thorough examination. Among these cases, 2, 083 (73.8%) received endoscopic examination actually, and 55 cases of gastric cancer were discovered. The discovery rate of gastric cancer was 0.336 per cent.
35 cases of these 55 gastric cancer were operated in the surgical department of our hospital. 34 cases were resected (rate of resection was 97.1%) and 33 cases were resected curatively (rate of curative resection was 94.3%). These results were better than that of gastric cancer cases from out-patient clinic of the same period. The results of cases from out-patient clinic of our hospital were: total number of cases 321, resected cases 254 (79.1%), curative resection 189 cases (58.9%), respectively.
3.Factors Requiring Midazolam in Addition to Systemic Opioids to Control Dyspnea in Cancer Patients at the End of Life
Yuka OKUDA ; Toshiyuki KURIYAMA ; Yoshi TSUKIYAMA ; Yoshinobu MATSUDA ; Takashi YAMAGUCHI ; Masanori MORI ; Toshio SHIMOKAWA ; Tomoyuki KAWAMATA
Palliative Care Research 2023;18(4):247-252
Background: Factors requiring midazolam in addition to systemic opioids to control dyspnea in cancer patients have yet to be evaluated. Methods: We retrospectively analyzed data for cancer patients who received systemic opioids to relieve dyspnea from April 2019 to July 2021 in Wakayama Medical University Hospital, Japan. Patients were divided into an opioid-alone group and an opioid plus midazolam group, according to the treatment of dyspnea. Results: The total of 107 patients included 85 patients (79.4%) in the opioid alone group and 22 patients (20.6%) in the opioid plus midazolam group. Age<60 years (p=0.004) and male sex (p=0.034) was significantly associated with the addition of midazolam. Multivariate analysis found age <60 years (OR=5.34, 95%CI: 1.66–17.21; p=0.005) was associated with the addition of midazolam. Conclusion: Age <60 years is factor requiring midazolam in addition to systemic opioids to control dyspnea in cancer patients.